Paul Ornstein, PhD

Paul L. Ornstein, PhD is a passionate Drug Hunter. After training as a synthetic organic chemist, Dr. Ornstein joined Eli Lilly, where for 28 years he was a drug discovery medicinal chemist. Upon retiring, he joined the Roosevelt University College of Pharmacy, and after 5 years, he moved to the Medical College of Wisconsin Pharmacy School. Paul is now retired from academia to focus full-time on consulting. He is an accomplished medicinal chemist in the neuroscience area, having led multidisciplinary scientific teams that delivered 8 clinical candidates. Most of Dr. Ornstein’s research efforts have focused on the discovery of novel ligands for excitatory amino acid receptors. Notable among these are the AMPA/kainate antagonist tezampanel and the kainate antagonist dasolampanel, plus the mGlu2,3 antagonist LY341495. His research efforts resulted in 57 issued US patents, 121 peer-reviewed publications, and 55 invited lectures on his research at scientific meetings and universities around the world. As a consultant, he has experience in third-party due diligence reviews and provide medicinal chemistry expertise to guide drug discovery programs towards clinical candidates. He is currently a Medicinal Chemistry Fellow at Inductive Bio, working to help them apply their machine learning and AI skills toward the development of high impact predictive tools to guide drug discovery.

Senior Research Fellow, Eli Lilly and Company

Associate Professor of Medicinal Chemistry, College of Pharmacy, Roosevelt University

Associate Professor of Medicinal Chemistry, Medical College of Wisconsin, School of Pharmacy

Medicinal Chemistry Consultant, Apollo Drug Discovery Consulting

Medicinal Chemistry Fellow, Inductive Bio